RecruitingPhase 2NCT06393712
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
Studying Hereditary cerebral amyloid angiopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alnylam Pharmaceuticals
- Principal Investigator
- Medical DirectorAlnylam Pharmaceuticals
- Intervention
- Placebo(drug)
- Enrollment
- 200 target
- Eligibility
- 30 years · All sexes
- Timeline
- 2024 – 2029
Study locations (30)
- Clinical Trial Site, Los Angeles, California, United States
- Clinical Trial Site, Orange, California, United States
- Clinical Trial Site, Palo Alto, California, United States
- Clinical Trial Site, Sacramento, California, United States
- Clinical Trial Site, San Francisco, California, United States
- Clinical Trial Site, Aurora, Colorado, United States
- Clinical Trial Site, New Haven, Connecticut, United States
- Clinical Trial Site, Gainesville, Florida, United States
- Clinical Trial Site, Jacksonville, Florida, United States
- Clinical Trial Site, Maitland, Florida, United States
- Clinical Trial Site, Naples, Florida, United States
- Clinical Trial Site, Chicago, Illinois, United States
- Clinical Trial Site, Lexington, Kentucky, United States
- Clinical Trial Site, New Orleans, Louisiana, United States
- Clinical Trial Site, Boston, Massachusetts, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06393712 on ClinicalTrials.govOther trials for Hereditary cerebral amyloid angiopathy
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06714097Application of Digital Twins' Technology in Patients Who Had a Stroke, With Moyamoya Disease and With Cerebral Amyloid Angiopathy (CAA) During the Secondary Prevention Phase: A Proof of Concept Using a Randomized Control Trial (Clinical Study 6, STRATIF-AI Project)Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- RECRUITINGPHASE2NCT05709314A Study of AMDX-2011P in Participants With CAAAmydis Inc.
- RECRUITINGNCT04204642SEarchiNg biomarkErs Cerebral Amyloid Angiopathy (SENECA)Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- ACTIVE NOT RECRUITINGNCT06128824High Frequency Imaging in Cerebral Amyloid AngiopathyMartin Dichgans